United States Pharmaceuticals

Opus Genetics Inc (IRD)

Track

Over the last 90 days, Opus Genetics Inc. has seen significant insider selling, with a net value of over $7.5 million. This trend is primarily driven by large sell-offs from institutional investors and executives. The company's stock has experienced a notable decline of 23.5% in the same period, and the last earnings report showed a significant miss.
Ticker: IRD Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Opus Genetics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Foundation Fighting Blindness Retinal Degeneration Fund
See Remarks
1 sale — total 7,395,000 USD
Sale 18 May 2026
Value US$1,479,216.49 | Price 411.41 | Shares 12,192
Sale 23 Apr 2026
Value US$4,509,417.01 | Price 165.83 | Shares 54,747
Proposed sale 23 Apr 2026
Value US$1,401,227.78 | Price 435.26 | Shares 91,378
Sale 23 Apr 2026
Value US$40,657.63 | Price 5.18 | Shares 7,842
Proposed sale 23 Apr 2026
Value US$40,657.63 | Price 5.18 | Shares 7,842
Sale 23 Apr 2026
Value US$49,647.42 | Price 5.22 | Shares 9,511
Proposed sale 23 Apr 2026
Value US$127,326.87 | Price 13.39 | Shares 9,511
Sale 23 Apr 2026
Value US$8,539.76 | Price 5.20 | Shares 1,641
Sale 23 Apr 2026
Value US$24,519.28 | Price 5.22 | Shares 4,697
Proposed sale 23 Apr 2026
Value US$24,519.28 | Price 5.22 | Shares 4,697
Sale 23 Apr 2026
Value US$39,155.80 | Price 5.19 | Shares 7,542
Proposed sale 23 Apr 2026
Value US$39,155.80 | Price 5.19 | Shares 7,542
Sale 16 Mar 2026
Value US$14,769.92 | Price 5.25 | Shares 2,816
Sale 16 Mar 2026
Value US$19,525.12 | Price 5.25 | Shares 3,719
Sale 16 Mar 2026
Value US$127,326.87 | Price 5.21 | Shares 24,438
Proposed sale 16 Mar 2026
Value US$127,326.87 | Price 5.21 | Shares 24,438
Sale 16 Mar 2026
Value US$19,046.11 | Price 5.12 | Shares 3,719
Buy 29 Dec 2025
Value US$163,418.70 | Price 1.97 | Shares 83,000
Buy 29 Dec 2025
Value US$160,274.70 | Price 1.98 | Shares 81,000
Sale 9 Dec 2025
Value US$8,600,000.00 | Price 2.15 | Shares 4,000,000
Buy 26 Dec 2024
Value US$97,600.00 | Price 0.98 | Shares 100,000
Buy 21 Nov 2024
Value US$9,834.00 | Price 0.98 | Shares 10,000
Buy 18 Nov 2024
Value US$9,942.83 | Price 1.02 | Shares 9,706
Buy 15 Nov 2024
Value US$91,215.00 | Price 1.01 | Shares 90,294
Buy 22 May 2024
Value US$6,177.50 | Price 1.77 | Shares 3,500
Buy 17 May 2024
Value US$8,772.50 | Price 1.75 | Shares 5,000
Buy 17 May 2024
Value US$8,772.50 | Price 1.75 | Shares 5,000
Buy 21 Mar 2024
Value US$21,000.00 | Price 2.10 | Shares 10,000
Buy 21 Mar 2024
Value US$4,100.00 | Price 2.05 | Shares 2,000
Buy 18 Mar 2024
Value US$49,050.00 | Price 1.96 | Shares 25,000
Buy 20 May 2022
Value US$9,950.00 | Price 1.99 | Shares 5,000
Buy 20 May 2022
Value US$25,300.00 | Price 2.02 | Shares 12,500
Buy 19 May 2022
Value US$25,878.75 | Price 2.07 | Shares 12,500
Buy 13 Dec 2021
Value US$30,112.50 | Price 3.65 | Shares 8,250
Buy 18 Nov 2021
Value US$7,000.00 | Price 3.50 | Shares 2,000
Buy 19 Nov 2020
Value US$0.00 | Price 0.00 | Shares 8,865
Buy 19 Nov 2020
Value US$0.00 | Price 0.00 | Shares 4,434
Buy 19 Nov 2020
Value US$0.00 | Price 0.00 | Shares 11,524
Buy 19 Nov 2020
Value US$0.00 | Price 0.00 | Shares 17,730
Buy 19 Nov 2020
Value US$0.00 | Price 0.00 | Shares 8,865
Buy 19 Nov 2020
Value US$0.00 | Price 0.00 | Shares 1,771
Buy 31 Jan 2019
Value US$6,380.00 | Price 0.64 | Shares 10,000
Buy 30 Jan 2019
Value US$12,960.00 | Price 0.65 | Shares 20,000
Buy 29 Jan 2019
Value US$9,141.00 | Price 0.61 | Shares 15,000
Buy 29 Jan 2019
Value US$31,720.00 | Price 0.63 | Shares 50,000
Planned sale 10 Apr 2017
Value US$175,375.00 | Price 0.70 | Shares 250,000
Planned sale 12 Jan 2015
Value US$45,492.30 | Price 0.91 | Shares 49,800
Planned sale 12 Jan 2015
Value US$44,263.28 | Price 0.91 | Shares 48,444
Planned sale 9 Jan 2015
Value US$172,707.96 | Price 0.92 | Shares 188,690
Planned sale 9 Jan 2015
Value US$170,477.09 | Price 0.92 | Shares 186,212
Planned sale 8 Jan 2015
Value US$70,935.31 | Price 0.90 | Shares 78,782
Planned sale 8 Jan 2015
Value US$72,032.00 | Price 0.90 | Shares 80,000
Sale 12 Jun 2014
Value US$134,436.11 | Price 0.99 | Shares 136,193
Sale 9 Sep 2013
Value US$32,474.95 | Price 0.46 | Shares 71,139
Buy 3 Oct 2011
Value US$2,600.00 | Price 1.04 | Shares 2,500
Buy 9 Sep 2011
Value US$6,150.00 | Price 1.23 | Shares 5,000
Buy 9 Sep 2011
Value US$16,212.70 | Price 1.22 | Shares 13,300
Buy 9 Sep 2011
Value US$67,222.00 | Price 1.22 | Shares 55,100
Buy 9 Sep 2011
Value US$7,986.00 | Price 1.21 | Shares 6,600
Buy 8 Sep 2011
Value US$16,185.00 | Price 1.08 | Shares 15,000
Buy 8 Sep 2011
Value US$2,747.50 | Price 1.10 | Shares 2,500
Buy 8 Sep 2011
Value US$6,444.08 | Price 1.09 | Shares 5,912
Buy 8 Sep 2011
Value US$15,180.00 | Price 1.10 | Shares 13,800
Buy 8 Sep 2011
Value US$8,064.00 | Price 1.12 | Shares 7,200
Buy 8 Sep 2011
Value US$663.85 | Price 1.13 | Shares 588
Buy 7 Sep 2011
Value US$5,200.00 | Price 1.04 | Shares 5,000
Buy 6 Sep 2011
Value US$283.50 | Price 0.95 | Shares 300
Buy 6 Sep 2011
Value US$4,252.50 | Price 0.95 | Shares 4,500
Buy 6 Sep 2011
Value US$283.20 | Price 0.94 | Shares 300
Buy 6 Sep 2011
Value US$3,685.50 | Price 0.95 | Shares 3,900
Buy 6 Sep 2011
Value US$5,019.10 | Price 0.95 | Shares 5,300
Buy 6 Sep 2011
Value US$2,317.70 | Price 0.95 | Shares 2,450
Buy 6 Sep 2011
Value US$3,081.00 | Price 0.95 | Shares 3,250
Buy 18 May 2011
Value US$1,320,582.18 | Price 1.31 | Shares 1,008,078
Buy 1 Apr 2011
Value US$391,432.12 | Price 1.22 | Shares 320,846
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-20 2026-05-18 S Sale
Foundation Fighting Blindness Retinal Degeneration Fund

See Remarks

Non-Executive Director
12,192 -38.3%
411.41
US$1,479,216 		12,192 -38.3% 411.41 US$1,479,216
2026-04-27 2026-04-23 S Sale
3.2
YERXA BENJAMIN R

President

Executive Director
54,747 +26.8%
165.83
US$4,509,417 		54,747 +26.8% 165.83 US$4,509,417
2026-04-27 2026-04-23 S Sale
3.1
Gagnon Robert E.

Chief Financial Officer

Officer
65,473 -34.0%
263.02
US$3,758,432 		65,473 -34.0% 263.02 US$3,758,432
2026-04-27 2026-04-23 S Sale
3.3
Magrath George

Chief Executive Officer

Executive Director
9,511 -0.5%
5.22
US$49,647 		9,511 -0.5% 5.22 US$49,647
2026-04-27 2026-04-23 S Sale
Zaremba Rabourn Amy

Head of Fin. Quality Assurance

Officer
1,641 -0.9%
5.20
US$8,540 		1,641 -0.9% 5.20 US$8,540
2026-04-27 2026-04-23 S Sale
2.8
SCHACHLE JOSEPH K

Chief Operating Officer

Officer
4,697 -1.6%
5.22
US$24,519 		4,697 -1.6% 5.22 US$24,519
2026-04-27 2026-04-23 S Sale
2.7
Jayagopal Ashwath

Chief Scientific & Dev. Ofc.

Officer
7,542 -1.5%
5.19
US$39,156 		7,542 -1.5% 5.19 US$39,156
2026-04-23 2026-04-23 PrS Proposed sale
2.8
SCHACHLE JOSEPH K

Officer

Officer
4,697
5.22
US$24,519 		4,697 5.22 US$24,519
2026-04-23 2026-04-23 PrS Proposed sale
3.2
YERXA BENJAMIN R

Officer

Officer
7,470
5.24
US$39,121 		7,470 5.24 US$39,121
2026-04-23 2026-04-23 PrS Proposed sale
3.3
Magrath George

Officer

Officer
9,511
13.39
US$127,327 		9,511 13.39 US$127,327
2026-04-23 2026-04-23 PrS Proposed sale
3.1
Gagnon Robert E.

Officer

Officer
7,842
5.18
US$40,658 		7,842 5.18 US$40,658
2026-04-23 2026-04-23 PrS Proposed sale
2.7
Jayagopal Ashwath

Officer

Officer
7,542
5.19
US$39,156 		7,542 5.19 US$39,156
2026-03-18 2026-03-16 S Sale
Zaremba Rabourn Amy

Head of Fin. Quality Assurance

Officer
2,816 -1.5%
5.25
US$14,770 		2,816 -1.5% 5.25 US$14,770
2026-03-18 2026-03-16 S Sale
2.8
SCHACHLE JOSEPH K

Chief Operating Officer

Officer
3,719 -1.2%
5.25
US$19,525 		3,719 -1.2% 5.25 US$19,525
2026-03-18 2026-03-16 S Sale
3.3
Magrath George

Chief Executive Officer

Executive Director
24,438 -1.4%
5.21
US$127,327 		24,438 -1.4% 5.21 US$127,327
2026-03-18 2026-03-16 S Sale
2.7
Jayagopal Ashwath

Chief Scientific & Dev. Ofc.

Officer
3,719 -0.7%
5.12
US$19,046 		3,719 -0.7% 5.12 US$19,046
2026-03-16 2026-03-16 PrS Proposed sale
3.3
Magrath George

Officer

Officer
24,438
5.21
US$127,327 		24,438 5.21 US$127,327
2025-12-31 2025-12-29 B Purchase
3.4
Gallagher Cam
Non-Executive Director
83,000 +inf%
1.97
US$163,419 		83,000 +inf% 1.97 US$163,419
2025-12-31 2025-12-29 B Purchase
3.4
Gallagher Cam
Non-Executive Director
81,000 +4.5%
1.98
US$160,275 		81,000 +4.5% 1.98 US$160,275
2025-12-11 2025-12-09 S Sale
Foundation Fighting Blindness Retinal Degeneration Fund

See Remarks

Non-Executive Director
4,000,000 -42.1%
2.15
US$8,600,000 		4,000,000 -42.1% 2.15 US$8,600,000
2024-12-30 2024-12-26 B Purchase
3.3
Magrath George

Chief Executive Officer

Officer
100,000 +20.0%
0.98
US$97,600 		100,000 +20.0% 0.98 US$97,600
2024-11-25 2024-11-21 B Purchase
3.2
YERXA BENJAMIN R

President

Executive Director
10,000 +3.0%
0.98
US$9,834 		10,000 +3.0% 0.98 US$9,834
2024-11-19 2024-11-18 B Purchase
3.3
Magrath George

Chief Executive Officer

Officer
9,706 +2.0%
1.02
US$9,943 		9,706 +2.0% 1.02 US$9,943
2024-11-19 2024-11-15 B Purchase
3.3
Magrath George

Chief Executive Officer

Officer
90,294 +23.0%
1.01
US$91,215 		90,294 +23.0% 1.01 US$91,215
2024-05-24 2024-05-22 B Purchase
2.7
Jayagopal Ashwath

Chief Scientific & Dev. Ofc.

Officer
3,500 +4.7%
1.77
US$6,178 		3,500 +4.7% 1.77 US$6,178
2024-05-21 2024-05-17 B Purchase
3.3
Magrath George

Chief Executive Officer

Officer
5,000 +1.2%
1.75
US$8,772 		5,000 +1.2% 1.75 US$8,772
2024-05-21 2024-05-17 B Purchase
3.3
Magrath George

Chief Executive Officer

Officer
5,000 +1.2%
1.75
US$8,772 		5,000 +1.2% 1.75 US$8,772
2024-03-25 2024-03-21 B Purchase
0.7
Jhaveri Nirav S.

Chief Financial Officer

Officer
10,000 +7.1%
2.10
US$21,000 		10,000 +7.1% 2.10 US$21,000
2024-03-25 2024-03-21 B Purchase
2.8
SCHACHLE JOSEPH K

Chief Operating Officer

Officer
2,000 +inf%
2.05
US$4,100 		2,000 +inf% 2.05 US$4,100
2024-03-20 2024-03-18 B Purchase
3.3
Magrath George

Chief Executive Officer

Officer
25,000 +6.2%
1.96
US$49,050 		25,000 +6.2% 1.96 US$49,050
2022-05-24 2022-05-20 B Purchase
3.4
MANUSO JAMES S J
Non-Executive Director
5,000 +30.2%
1.99
US$9,950 		5,000 +30.2% 1.99 US$9,950
2022-05-23 2022-05-20 B Purchase
2.8
Sooch Mina

President and CEO

Executive Director
12,500 +3.0%
2.02
US$25,300 		12,500 +3.0% 2.02 US$25,300
2022-05-23 2022-05-19 B Purchase
2.8
Sooch Mina

President and CEO

Executive Director
12,500 +3.1%
2.07
US$25,879 		12,500 +3.1% 2.07 US$25,879
2021-12-14 2021-12-13 B Purchase
1.4
Pepose Jay
Non-Executive Director
8,250 +56.0%
3.65
US$30,112 		8,250 +56.0% 3.65 US$30,112
2021-11-22 2021-11-18 B Purchase
3.4
MANUSO JAMES S J
Non-Executive Director
2,000 +13.7%
3.50
US$7,000 		2,000 +13.7% 3.50 US$7,000
2020-11-25 2020-11-19 B Purchase
3.4
Gallagher Cam
Non-Executive Director
8,865
0.00
US$0 		8,865 0.00 US$0
2020-11-25 2020-11-19 B Purchase
3.4
MANUSO JAMES S J
Non-Executive Director
4,434
0.00
US$0 		4,434 0.00 US$0
2020-11-25 2020-11-19 B Purchase
2.8
Sooch Mina

President and CEO

Executive Director
11,524
0.00
US$0 		11,524 0.00 US$0
2020-11-25 2020-11-19 B Purchase
Rodgers Richard J
Non-Executive Director
17,730
0.00
US$0 		17,730 0.00 US$0
2020-11-25 2020-11-19 B Purchase
Ainsworth Sean
Non-Executive Director
8,865
0.00
US$0 		8,865 0.00 US$0
2020-11-25 2020-11-19 B Purchase
MEYER ALAN R
Non-Executive Director
1,771
0.00
US$0 		1,771 0.00 US$0
2019-02-04 2019-01-31 B Purchase
0.6
Beever Charles
10,000 +1000.0%
0.64
US$6,380 		10,000 +1000.0% 0.64 US$6,380
2019-01-31 2019-01-30 B Purchase
0.6
Nolan Lisa

Chief Business Officer
20,000 +1230.8%
0.65
US$12,960 		20,000 +1230.8% 0.65 US$12,960
2019-01-31 2019-01-29 B Purchase
0.6
Price Ben Gil
15,000 +inf%
0.61
US$9,141 		15,000 +inf% 0.61 US$9,141
2019-01-30 2019-01-29 B Purchase
1.2
Swirsky Douglas J

President and CEO
50,000 +inf%
0.63
US$31,720 		50,000 +inf% 0.63 US$31,720
2017-04-12 2017-04-10 PlS Planned sale Ahn Chang Ho
250,000 -4.0%
0.70
US$175,375 		250,000 -4.0% 0.70 US$175,375
2015-01-12 2015-01-12 PlS Planned sale Jeong Tae Heum

Chief Financial Officer

Officer
49,800 -9.0%
0.91
US$45,492 		49,800 -9.0% 0.91 US$45,492
2015-01-12 2015-01-12 PlS Planned sale Ahn Chang Ho Non-Executive Director
48,444 -0.8%
0.91
US$44,263 		48,444 -0.8% 0.91 US$44,263
2015-01-12 2015-01-09 PlS Planned sale Jeong Tae Heum

Chief Financial Officer

Officer
188,690 -27.2%
0.92
US$172,708 		188,690 -27.2% 0.92 US$172,708
2015-01-12 2015-01-09 PlS Planned sale Ahn Chang Ho Non-Executive Director
186,212 -3.0%
0.92
US$170,477 		186,212 -3.0% 0.92 US$170,477
2015-01-12 2015-01-08 PlS Planned sale Jeong Tae Heum

Chief Financial Officer

Officer
78,782 -13.5%
0.90
US$70,935 		78,782 -13.5% 0.90 US$70,935
2015-01-12 2015-01-08 PlS Planned sale Ahn Chang Ho Non-Executive Director
80,000 -1.3%
0.90
US$72,032 		80,000 -1.3% 0.90 US$72,032
2014-06-16 2014-06-12 S Sale Ahn Chang Ho Non-Executive Director
136,193 -2.0%
0.99
US$134,436 		136,193 -2.0% 0.99 US$134,436
2013-09-11 2013-09-09 S Sale Jeong Tae Heum

Chief Financial Officer

Officer
71,139 -12.3%
0.46
US$32,475 		71,139 -12.3% 0.46 US$32,475
2011-10-21 2011-10-03 B Purchase Kivel Richard Non-Executive Director
2,500 +inf%
1.04
US$2,600 		2,500 +inf% 1.04 US$2,600
2011-09-12 2011-09-09 B Purchase Brandt Peter C. Non-Executive Director
5,000 +3.4%
1.23
US$6,150 		5,000 +3.4% 1.23 US$6,150
2011-09-12 2011-09-09 B Purchase Brandt Peter C. Non-Executive Director
13,300 +10.1%
1.22
US$16,213 		13,300 +10.1% 1.22 US$16,213
2011-09-12 2011-09-09 B Purchase Brandt Peter C. Non-Executive Director
55,100 +71.9%
1.22
US$67,222 		55,100 +71.9% 1.22 US$67,222
2011-09-12 2011-09-09 B Purchase Brandt Peter C. Non-Executive Director
6,600 +9.4%
1.21
US$7,986 		6,600 +9.4% 1.21 US$7,986
2011-09-12 2011-09-08 B Purchase Brandt Peter C. Non-Executive Director
15,000 +27.3%
1.08
US$16,185 		15,000 +27.3% 1.08 US$16,185
2011-09-12 2011-09-08 B Purchase Brandt Peter C. Non-Executive Director
2,500 +4.8%
1.10
US$2,748 		2,500 +4.8% 1.10 US$2,748
2011-09-12 2011-09-08 B Purchase Brandt Peter C. Non-Executive Director
5,912 +12.7%
1.09
US$6,444 		5,912 +12.7% 1.09 US$6,444
2011-09-12 2011-09-08 B Purchase Brandt Peter C. Non-Executive Director
13,800 +42.1%
1.10
US$15,180 		13,800 +42.1% 1.10 US$15,180
2011-09-12 2011-09-08 B Purchase Brandt Peter C. Non-Executive Director
7,200 +28.1%
1.12
US$8,064 		7,200 +28.1% 1.12 US$8,064
2011-09-12 2011-09-08 B Purchase Brandt Peter C. Non-Executive Director
588 +2.4%
1.13
US$664 		588 +2.4% 1.13 US$664
2011-09-08 2011-09-07 B Purchase Brandt Peter C. Non-Executive Director
5,000 +25.0%
1.04
US$5,200 		5,000 +25.0% 1.04 US$5,200
2011-09-08 2011-09-06 B Purchase Brandt Peter C. Non-Executive Director
300 +1.5%
0.95
US$284 		300 +1.5% 0.95 US$284
2011-09-08 2011-09-06 B Purchase Brandt Peter C. Non-Executive Director
4,500 +29.6%
0.95
US$4,252 		4,500 +29.6% 0.95 US$4,252
2011-09-08 2011-09-06 B Purchase Brandt Peter C. Non-Executive Director
300 +2.0%
0.94
US$283 		300 +2.0% 0.94 US$283
2011-09-08 2011-09-06 B Purchase Brandt Peter C. Non-Executive Director
3,900 +35.5%
0.95
US$3,686 		3,900 +35.5% 0.95 US$3,686
2011-09-08 2011-09-06 B Purchase Brandt Peter C. Non-Executive Director
5,300 +93.0%
0.95
US$5,019 		5,300 +93.0% 0.95 US$5,019
2011-09-08 2011-09-06 B Purchase Brandt Peter C. Non-Executive Director
2,450 +75.4%
0.95
US$2,318 		2,450 +75.4% 0.95 US$2,318
2011-09-08 2011-09-06 B Purchase Brandt Peter C. Non-Executive Director
3,250 +inf%
0.95
US$3,081 		3,250 +inf% 0.95 US$3,081
2011-05-20 2011-05-18 B Purchase Ahn Chang Ho

Chairman & CEO

Executive Director Large shareholder
1,008,078 +9.8%
1.31
US$1,320,582 		1,008,078 +9.8% 1.31 US$1,320,582
2011-04-05 2011-04-01 B Purchase Ahn Chang Ho

Chairman & CEO

Executive Director Large shareholder
320,846 +3.2%
1.22
US$391,432 		320,846 +3.2% 1.22 US$391,432
Explore more

More insider trading research around Opus Genetics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America